[{"id":"8e333d31-cdb1-4edd-a209-db63d88f24e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087263","created_at":"2023-10-17T15:12:53.355Z","updated_at":"2024-07-02T16:35:08.034Z","phase":"Phase 2","brief_title":"Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.","source_id_and_acronym":"NCT06087263","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" SDHB","pipe":" | ","alterations":" KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation","tags":["SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 07/01/2032","primary_completion_date":" 07/01/2032","study_txt":" Completion: 07/01/2034","study_completion_date":" 07/01/2034","last_update_posted":"2024-04-23"},{"id":"d1bc1259-71d0-45e4-a4ce-99f4232d61c4","acronym":"AZURE","url":"https://clinicaltrials.gov/study/NCT05609942","created_at":"2023-04-03T15:02:58.943Z","updated_at":"2024-07-02T16:35:11.975Z","phase":"Phase 1/2","brief_title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","source_id_and_acronym":"NCT05609942 - AZURE","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation • KIT D816V • KIT exon 17 mutation • PDGFRA fusion","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation • KIT D816V • KIT exon 17 mutation • PDGFRA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • elenestinib (BLU-263)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2024-04-02"},{"id":"6930bd13-a689-4284-b6bf-affbebb0e167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366816","created_at":"2022-05-09T11:56:34.398Z","updated_at":"2024-07-02T16:35:32.170Z","phase":"Phase 2","brief_title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","source_id_and_acronym":"NCT05366816","lead_sponsor":"University of Miami","biomarkers":" KIT","pipe":" | ","alterations":" KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/17/2023","start_date":" 10/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-10-23"},{"id":"adc60e89-0c9c-4cc8-bd12-3a3c5b7efc48","acronym":"","url":"https://clinicaltrials.gov/study/NCT01543113","created_at":"2021-01-18T06:31:19.399Z","updated_at":"2024-07-02T16:35:47.212Z","phase":"","brief_title":"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project","source_id_and_acronym":"NCT01543113","lead_sponsor":"Rennes University Hospital","biomarkers":" KIT • RAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation"],"overall_status":"Completed","enrollment":" Enrollment 288","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2023-05-24"},{"id":"146c9420-e555-47fd-8fcd-cac5b5961016","acronym":"REGISTRI","url":"https://clinicaltrials.gov/study/NCT02638766","created_at":"2021-01-18T12:50:04.935Z","updated_at":"2024-07-02T16:35:52.222Z","phase":"Phase 2","brief_title":"Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST","source_id_and_acronym":"NCT02638766 - REGISTRI","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation • KIT wild-type • PDGFR wild-type","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation • KIT wild-type • PDGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2021","study_completion_date":" 08/31/2021","last_update_posted":"2023-03-27"},{"id":"ea5d6031-d473-42c0-8a28-91a62279cacc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03609424","created_at":"2021-01-18T17:44:34.659Z","updated_at":"2024-07-02T16:35:58.343Z","phase":"Phase 1/2","brief_title":"PDR001 Plus Imatinib for Metastatic or Unresectable GIST","source_id_and_acronym":"NCT03609424","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2023-01-02"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"a18489c2-2502-40c8-8b48-a5da6407cf6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02606097","created_at":"2021-01-18T12:39:32.400Z","updated_at":"2024-07-02T16:37:01.465Z","phase":"Phase 2","brief_title":"Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation","source_id_and_acronym":"NCT02606097","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 17 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2019-03-21"}]